In pulmonary arterial hypertension (PAH), blood vessels in the lungs are narrowed, blocked or destroyed. The damage slows blood flow through the lungs, and blood pressure in the lung arteries rises. How the design of clinical trials has evolved in recent years is discussed in this touchRESPIRATORY interview with Dr Ioana Preston (Tufts University School of Medicine, Boston, MA, USA) as well as the need for patient-reported outcomes and the importance of patient involvement in trial design.
The presentation titled ‘The Future of Clinical Trials in PH: Novel Trial Designs and Endpoints’ was presented at the Pulmonary Hypertension Association, June 10-12, 2022
Questions
- How has the design of clinical trials evolved in recent years and what novel endpoints are emerging?
- Could you tell us a little about the need for patient-reported outcomes and the importance of patient involvement in trial design?
Disclosures: Ioana Preston discloses grant/research support from Acceleron, Janssen & United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the PHA Hybrid Congress 2022.
